SMARTOncology Tumor Insights provides data-driven insights into the future market dynamics for over 25 tumors.

With a forward-looking focus on the clinical landscape, SMARTOncology Tumor Insights is the best way to understand your market opportunity, access detailed clinical data, and receive updates on the changing landscape.

Oncology is the cornerstone of SmartAnalysts consulting business, and we have developed the series as a foundation for our clients' key clinical and commercial development and BD&L decisions.

Have confidence that you understand the implications of the changing landscape and immuno-oncology activities, and that you know what's required to inform clinical investment decisions.

With the SMARTOncology Tumor Insights, you will:

  • Obtain a forward-looking perspective and expert views* on key tumors, in order to shape commercial and clinical decisions for pipeline assets and BD opportunities
  • Understand how the competitive dynamics would impact the treatment paradigm in the coming 3-5 years
  • Acquire comprehensive foundational data with rich clinical data and insights
  • Keep track of the immunotherapy landscape, including outcomes that may impact strategic decisions on an IO/ non-IO in the portfolio
  • Stay current, with updates delivered twice each year
  • Get a global perspective, with insights on the US, EU and select Asia-Pacific markets
  • Consolidate key insights and data in one concise report - and avoid internal "fire drills" accessing data
  • Quickly get up to speed on a tumor when evaluating a BD&L opportunity
  • Easily cut-and-paste data and slides into your own presentations

Table of Contents

Executive Summary

Disease Overview

  • Anatomy/Histology
  • Symptoms/Diagnosis
  • Staging/Classification

Epidemiology
  • Treatment starts by line of therapy for 2016 - 2025*
Current Treatment Landscape

  • Treatment Algorithm
  • Benchmarks
  • Timelines: Approvals and Patent Expirations
  • Unmet Needs

Emerging Treatment Landscape

  • Clinical Pipeline Activity
  • Summary of IO Activity
  • Summary of Key Emerging Agents
  • Emerging Patient Segments

Current and Emerging Biomarkers
Pricing, Reimbursement and Cost-effectiveness Analysis
Clinical Development Pathway in Key Disease Opportunities
Appendix

  • Trial Profiles of Key Emerging Agents
  • Trial Failures

2017 Planner

Available Now

Solid Tumors


Esophageal Cancer
NSCLC
Gastric Cancer
SCLC
Pancreatic
Mesothelioma
HCC
TNBC
Colorectal
HER2+ Breast Cancer
RCC
HER2 Neg HR+ Breast Cancer
Bladder Cancer
Ovarian Cancer
Prostate
Melanoma
 
SCCHN

Hematologic Malignancies


AML
Myelofibrosis
iNHL
MDS
aNHL
Multiple Myeloma
CLL
ALL
CML
Updates available following
AACR/ASCO/EHA (May-Aug 2017)

Additional tumors can be covered or we can customize reports, as required


Our Practice lead Anshu Mittal Roy, PhD, would be happy to take you through the SMARTOncology Tumor Insights, and discuss how the reports and our consulting services can help inform key decision points for your pipeline and business. Please contact Trish Kane at tkane@smartanalyst.com to schedule a brief web conference.

 


GLOBAL HEADQUARTERS
(New York, USA)

9 East 38th Street, 8th Floor,
New York 10016
Tel.: (212) 331-0010
Fax: (212) 331-0011
Fax: (866) 256-9402

EUROPE
(London, UK)

Hertfordshire, London, United Kingdom
Tel.: +44 (0) 1920 412 899
Mob.: +44 (0) 7903 070071

ASIA PACIFIC
(Gurgaon, INDIA)

14th Floor, Tower D, Cyber Green,
DLF City Phase-III,
Gurgaon 122002, Haryana, India
Tel.: 91-124-4313800,
91-124-4147900, 91-124-4147910-13
Fax: 91-124-4313899

Latest SMARTOncology Newsletter

click here to download

Subscribe

Latest SMARTImmunology Newsletter

click here to download